Everest Medicines

News

22 2021/03

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava^™ for the Treatment of Complicated Intra-abdominal Infections
22 2021/03

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020
19 2021/03

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021
01 2021/03

Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
18 2021/02

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
21 2021/01

Everest Medicines CEO Awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award
18 2021/01

Everest Medicines Announces Amended Agreement with Spero Therapeutics
06 2021/01

Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
06 2021/01

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
22 2020/12

Everest Medicines Appoints Lan Kang to Board of Directors
09 2020/12

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy^™ (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
02 2020/12

Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号